

DETAILED ACTION

Claims 1-12, 14 and 17 are currently pending in the instant application, appear allowable over the prior art of record and have been renumbered as claims 1-14.

Response to Amendment and Arguments

Applicants' amendment filed 26 February 2010 has overcome the objection to claim 8; has overcome the 35 USC 112 1st paragraph rejection of claim 5; and has overcome the 35 USC 112 1st paragraph rejection of claims 13, 15 and 16. In regards to claim 17, applicants' arguments have been considered and are persuasive. Applicant has directed the examiner to pages 2-4 wherein the compounds of the formula I are taught to inhibit factor Xa, VIIa and IXa and page 4 which discloses the use for the compounds in the treatment of thrombosis. Therefore, the 35 USC 112 1st paragraph rejection of claim 17 is also withdrawn.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Harry B. Shubin on 3 March 2010.

The application has been amended as follows:

1. Amend claim 11 by deleting "a" at the beginning of the claim and inserting "A" in its place.

2. Amend claim 11 by deleting "andpharmaceutically" from the last line of the claim and inserting "and pharmaceutically" in its place.
3. Add the following sentence to the line following the title of the specification:
-- This application is a 371 of PCT/EP04/05088, filed May 12, 2004.--

Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to products of the formula I, processes of preparation and methods of use. The novel and nonobvious aspect of this invention involves the substituents on formula I. The closest prior art of record fails to teach or suggest applicants' instantly claimed invention.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (571) 272-0696. Mrs. Anderson can normally be reached Monday through Friday from 6:00am until 2:30pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*/Rebecca Anderson/
Primary Examiner, AU 1626*

4 March 2010

Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600